Immunocore Holdings (IMCR) Net Income (2021 - 2026)
Immunocore Holdings (IMCR) posted Net Income of $13.0 million for Q1 2026, up 143.15% sequentially from -$30.1 million in Q4 2025, and up 160.25% YoY from $5.0 million in Q1 2025.
Immunocore Holdings (IMCR) Net Income (2021 - 2026) Analysis & Trends
Immunocore Holdings has reported Net Income for 6 years, with the latest figure at $13.0 million in Q1 2026.
- Quarterly Net Income rose 160.25% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.6 million (down 27.23% YoY) and the FY2025 annual result came in at -$35.5 million, up 30.48% from the prior year.
- Net Income grew to $13.0 million in Q1 2026 per IMCR's latest filing, from -$30.1 million in the prior quarter.
- Over five years, Net Income peaked at $13.0 million in Q1 2026 and troughed at -$30.1 million in Q4 2025.
- A 5-year average of -$10.7 million and a median of -$14.6 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income jumped 864.24% in 2024, then plunged 102.24% in 2025.
- Over 5 years, Net Income stood at -$29.9 million in 2022, then jumped by 33.95% to -$19.7 million in 2023, then fell by 20.48% to -$23.8 million in 2024, then retreated by 26.46% to -$30.1 million in 2025, then jumped by 143.15% to $13.0 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered $13.0 million, -$30.1 million, and -$196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunocore Holdings | 1.76 Bn | 880.92 Mn | 114.84 Mn | -814,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -814,000.00 |
| Mar 31, 2026 | 12.97 Mn |
| Dec 31, 2025 | -30.06 Mn |
| Sep 30, 2025 | -196,000.00 |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | 4.98 Mn |
| Dec 31, 2024 | -23.77 Mn |
| Sep 30, 2024 | 8.74 Mn |
| Jun 30, 2024 | -11.63 Mn |
| Mar 31, 2024 | -24.48 Mn |
| Dec 31, 2023 | -19.73 Mn |
| Sep 30, 2023 | 906,000.00 |
| Jun 30, 2023 | -17.62 Mn |
| Mar 31, 2023 | -19.46 Mn |
| Dec 31, 2022 | -29.87 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | -19.69 Mn |
| Dec 31, 2021 | -53.10 Mn |
| Sep 30, 2021 | -41.54 Mn |